Analog Insulin — Competitive Intelligence Brief

Analog Insulin (Analog Insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin analog. Area: Diabetes.

marketed Insulin analog Insulin receptor (INSR) Diabetes Small molecule

Target snapshot

Analog Insulin (Analog Insulin) — National Institute of Neurosciences and Hospital, Dhaka. Analog insulin mimics endogenous insulin to regulate blood glucose by binding to insulin receptors and promoting glucose uptake in peripheral tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Analog Insulin TARGET	Analog Insulin	National Institute of Neurosciences and Hospital, Dhaka	marketed	Insulin analog	Insulin receptor (INSR)
Adlyxin	LIXISENATIDE	Sanofi-Aventis Us Llc	marketed	Insulin Analog [EPC]	Glucagon-like peptide 1 receptor	2016-01-01
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin analog class)

1. Generex Biotechnology Corp. · 1 drug in this class
2. Mylan Inc. · 1 drug in this class
3. National Institute of Neurosciences and Hospital, Dhaka · 1 drug in this class
4. University of Campania Luigi Vanvitelli · 1 drug in this class